A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR IN PREGNANT WOMEN WITH MILD-TO-MODERATE COVID-19
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary) ; Ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 14 Oct 2024 Planned End Date changed from 1 Jul 2025 to 29 Aug 2025.
- 14 Oct 2024 Planned primary completion date changed from 5 Feb 2025 to 5 Apr 2025.
- 24 Apr 2024 Status changed from suspended to recruiting.